Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 2Meningioma 2Lymphoma, B-Cell 2Glioma 2Glioblastoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Neoplasm Metastasis 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, B-Cell 1Carcinoma, Hepatocellular 1Carcinoma in Situ 1Carcinoma 1Burkitt Lymphoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 48Filgrastim 21fludarabine phosphate 19Rituximab 19Etoposide 19Peripheral Blood Stem Cell Transplantation 17fludarabine 16Prednisone 16Vincristine 15Cytarabine 12Doxorubicin 11blinatumomab 8Methotrexate 8Dexamethasone 8Cyclosporine 8Bortezomib 8venetoclax 7Vorinostat 7Paclitaxel 7Melphalan 7Lenalidomide 7Calcium Dobesilate 7Biopsy 7Specimen Handling 6Radiotherapy 6Indium 6tanespimycin 5aldesleukin 5Tacrolimus 5Inotuzumab Ozogamicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Burkitt Lymphoma × Magnetic Resonance Imaging × Clear all
NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡